ATHE
FDA said: keep going
Alterity Therapeutics says it came out of a Type C meeting with the FDA on the right side of the room. The agency gave positive feedback on the company’s planned Phase 3 program for ATH434, its candidate for Multiple System Atrophy, a nasty neurodegenerative disease with very few treatment options.
Why investors should care
For biotech, this is the part where the story either starts getting real or gets stuck in regulatory purgatory. Positive FDA feedback can de-risk the next step in development, because it suggests the company’s trial design and path forward are at least broadly aligned with what regulators want to see.
The not-so-glamorous biotech math
ATH434 is still a long way from becoming actual revenue, so this isn’t a “call your broker and pop champagne” moment. But it is the kind of update that can matter a lot for a small-cap drug developer, where every nod from the FDA can influence how much faith investors put into the pipeline.
Big picture
Alterity still has to execute, and biotech execution is famously where optimism goes to do laps. But for now, the company has a cleaner runway into Phase 3 planning than it did before the meeting.